New 5K position $NEPT


Today there was some very unusual options activity on $NEPT.  9500 FEB $4 calls were purchased.  We will have to wait and see tomorrow if the Open Interest goes down or up based on that transaction.  However, there is an upcoming catalyst for $ACST.  $ACST is a spin off company from $NEPT.  $NEPT owns 50% of $ACST and they are in the business of Krill Oil Omega-3.  With AMRN recent blunder ACST might have the edge here.  Nevertheless, it’s possible that ACST might be releasing data before the FEB expiration.

ACST had guided they expect to release Phase 2 results 1H 2014.  In addition, there is a rumor that they are expecting to reopen a plant that had an explosion November 8 2012.  With these two pending news items and unusual option activity I took the chance and bought 60 $2.50 FEB calls in the money at $1.05.    I’m targeting a $4.00 price break where I will close out the trade.  If the news doesn’t come or the action looks weak I will close out the trade.  Additionally, if the open interest in the $4 FEB calls decreases tomorrow I might just close out the position for a flat trade or maybe a small profit.

Outlay = 60 x $1.05 x 100 = $6300 + commissions

NEPT does have a few good things going for it though,  upcoming catalysts and the chart looks great for a breakout.



Account balance $10,428.55 (+109%)

5K Update 21 JAN 14 (+89%)

Just an update in the 5K challenge.  I closed out a short position in GALE today for a total of +$1394 gains.  I covered the 1K short shares at $5.65 which was quite good (pat myself on the back).  In the process I was trying to write puts to give myself a free trade into OPEX.  In the process, I wrote the wrong strike and I got upset and just closed the trade.  I was intending to write the $5 Feb PUTS and ended up clicking the $5.50 PUTS.  The stock was in a flash crash and I was rushing to get the order in place.   I was so upset with myself that on the bounce I just closed out the PUT spread for a +$79 profit.  Emotional trade, I know.  It happens occasionally.  Need to be more like a robot.




My next trade idea will be coming soon.  The bio market is red hot and I am trying to sit on my hands this week.  Let the trades develop and not rush into any new ones.  I see tons of overbought stocks.  I would like to short them but some still have great momentum carrying them.  The setup has to be there.

Account value stands at $9452.43 (+$4452.43 +89% ROI)

1/20/14 Update

Took a pretty big hit on AMRN Jan $2 calls last week.  I, along with many AMRN folks, did not see the double delay. My 5k game plan was simple; load up on AMRN Jan 2 calls knowing I will either lose premium if negative outcome OR have a multiplier if positive outcome. I am still bullish on AMRN spa. The FDA would have issued a CRL at this point. Anyways, there are so many blogs on the AMRN debacle so I’ll save my breath. I sold the calls for more than 50% loss.

Net loss of $2000 on the AMRN play.

Total Account after AMRN: $3200

My next play is a non-biotech, PLUG. I have purchased 150 Feb $6 calls for .10 ($1500 outlay). The chart looks hot and the retail hopium is off the charts. I am looking at a price target for sell trigger of 4.75-5.25


I will be watching closely so as to preserve value and not let Theta degrade this play. If it doesn’t move this week, I will exit.



ARIA momentum trade

Tried a trade today in ARIA and this just faded quick right after entry.  Very disappointing.  I cut the trade as quickly as I could.  The momentum and volume looked like it was there and then all of a sudden nobody was bidding up the stock and I just took the loss.

Here is what I was seeing in the trade.   Broke through that 6.75 level and I bought ITM $5.50 calls at $1.29.  Chased it a hair because the volume was there.  I bought right on the exact break of that trendline.  It continued higher and I was green in the options and then 4 candles later…. WOOSH a massive sell came in on the stock and killed the momentum.  At that point it was damage control and I exited as quickly as I could.



-$367 loss.


Account balance today stands at $8085.20 (+$3085.20 +61.7% ROI)


GALE Short Entry

Entered GALE short with 40 $7 APR PUTS at $1.75 on ridiculous market cap evaluation.  $800M Market cap for a company that currently sells one product called Abstral that brought in a whopping $1.3M in revenue for the Quarter ending Sept 30, 2013.  The company has approximately $55M in cash and equivalents and expects to have funding through 2015.

So, Neuvax is currently in Phase 3 trials and is not expected to be complete with patient enrollment until 2017.  By comparable standards, most cancer drug companies trade at market caps of $200-$300M for a one cancer drug company.  So, the market is pricing ABSTRAL at $500M?  Are you serious?

Continual price upgrade after price upgrade by Roth.  Maxim Upgraded GALE as well.  This is just beginning to look like an epic pump and dump in my opinion.  Needless to say, from a technical standpoint the price was WAY overbought and I shorted the open with puts when it failed to bounce off yesterdays high.  It broke down immediately and the selling was coming in pretty good.  I covered half the next day to reduce exposure primarily because the short interest is too high and the risk of squeeze is definitely in the back of my mind.


Today, Jan 16, Jim Cramer announced that he’s having the CEO of GALE on Mad Money.  That new alone sent retail longs into a panic frenzy of buying the stock back.  I exited the second half flat.


Trade has been closed.  +$471 profit



ACHN trade exit (Update)

This morning Achillion updated investors with the status of the company.

Article here

I was very interested in the Sovaprevir clinical hold status.  Was hoping the company would guide that we would see that hold lifted much sooner.  They guided 1H 2014 and also stated they have plenty of cash on hand.

Dr. Milind Deshpande, President and Chief Executive Officer of Achillion stated, “With our 2013 year-end cash balance projected to exceed $150 million, we believe we have sufficient capital to fund our operations into 2016 and achieve a number of value-creating milestones throughout this year with our HCV assets.”

However, the goal of this trade was to anticipate the news and make fast bucks for the $5K challenge.  $100K from $5K within a year is not easy so I have to act fast.  The Sovaprevir hold is just not going to be soon enough for me in this trade.  Although they are still in a very strong position fundamentally I exited the trade.

In addition, I was watching action at the open and there were very little buyers in the stock and it was meeting short term resistance as seen in the chart below.  In order for me to keep with this trade it had to go through $4 today and it did not.


Therefore, I closed the position for +$1908 profits and 34.7% gain.

Closing balance of $7982.44 (+59.6% ROI)



Only 1152% more to go!

Happy trading.

Update End of Week 10 JAN 14

Crazy week in the biotech stocks.  Started off the week with a terrible downgrade on $CELG by Goldman Sachs that was really unwarranted.  This set the tone for the biotech market early.  But this made for some great bounce trades mid week and into Friday.

Some interesting things happened this week.  $CHTP AdCom panel briefing documents were released and after review I actually feel like they aren’t that harsh.  Management has a history of defending Northera well so I expect a 60-70% chance of a positive outcome from the panel.  However, the stock was slaughtered.  Down 29% on the day.



Secondly, $MNKD had some very crazy action.  The stock was up through $7 Thursday on zero news only to be surprised by the FDA requesting and AdCom panel.  Wow!  This news couldn’t be any worse for longs.  AdCom panels have a history of being very harsh and could throw a wrench in the plans of approval on April of this year (PDUFA).  The surprise AdCom panel is concerning because Al Mann stated in conference calls that he did not expect one.  Additionally, this AdCom data of April 1st will likely delay the PDUFA decision and likely a higher chance of dilution by the company to raise funds.  All negatives for MNKD.  That being said, I’ll be looking forward to seeing the Afrezza data without PR fluff from the company.  This has been a very interesting story and I remain skeptical.  Rajalonghorn remains bullish and I hope he’s right because the public needs this therapy and it would be an awesome trade if approved.  Upon news of the panel MNKD shares closed down 16%.



Some other interesting plays came into the watchlist this week.  $ONTY, $RMTI, $AMRN, $ARIA, $GALE, and $RNN (Wow).  We’ll be watching these stocks for continuation throughout next week.

Lastly I am still holding $ACHN calls in my 5K challenge account and will intend to hold through $4 move.


1/9/14 Update for TW

Made a few trades today for net gain of $47. It was a tough day but I live to fight another day.

I will focus on my losing trade because this was a “teachable moment”.

ACST pm 2k shares @1.65 stopped out for -$500 loss. I have traded this pig a few times this year with small gains or small losses. No more on this one! Shortly after giving up vwap, it hit my stop. Not really much else to say.


The strategy that led to trade: daily chart revealed above avg volume yesterday. Resistance before open was 50 sma @1.47. Pre-market range with ~500k volume was 1.50-1.80.  I felt strongly that the next resistance was 100sma @ 1.95 or whole number 2.00.

Hindsight: wait until 10am when the “smart money” begins to drive pps. On the intraday, if you look at 10 am, there is a distinct change in momentum.



Updated 5K balance



The harder you work the luckier you get